ANCN Anchiano Therapeutics ADS

Anchiano Therapeutics Announces Appointment of Salar Roshan as Head of Business Development

Anchiano Therapeutics Announces Appointment of Salar Roshan as Head of Business Development

CAMBRIDGE, Mass., May 29, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq and TASE: ANCN) (“Anchiano”), a pivotal-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced the appointment of Salar Roshan as the Company’s Head of Business Development, effective May 28, 2019. Mr. Roshan will report to the Chief Executive Officer and will focus on driving Anchiano’s strategic initiatives.

“We are excited to have Salar lead our business development efforts,” said Frank Haluska, M.D., Ph.D., President and Chief Executive Officer of Anchiano. “Salar brings strong scientific and transactional experience in the biotechnology field where he previously led portfolio, corporate and business development efforts. He will articulate and execute our business development activities as we seek to stengthen our product pipeline.”

Mr. Roshan stated, “I am delighted to join this dynamic team and look forward to immediately contributing to the development of the company’s strategic focus in both the gene therapy and cancer treatment arenas, where Anchiano has established expertise and where there is great promise.”

About Salar Roshan

Mr. Roshan joins Anchiano Therapeutics from Curis, Inc., an anti-cancer biotechnology company, where he served as Head of Corporate Development and was responsible for overseeing all aspects of the company’s corporate and business development strategy. Prior to that, he led the partial spin-off of the R&D division of Baxter Biosciences into Baxalta. While at Baxalta, he was also responsible for several product launches and oversaw valuation and long range planning for the hemophilia portfolio, which grossed roughly $4 billion in annual sales prior to Baxalta’s merger with Shire PLC. Mr. Roshan has also held roles of increasing responsibility at Ironwood Pharmaceuticals, Takeda US, Millennium Pharmaceuticals, and Genzyme. Mr. Roshan received his M.Sc. in finance and his M.B.A. from Kelley School of Business at Indiana University, and his B.Sc. in biotechnology from Northeastern University.

About Anchiano

Anchiano is a pivotal-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, with offices in Cambridge, MA, and Jerusalem, Israel. Anchiano’s most advanced product candidate, inodiftagene, is in development as a treatment for non-muscle-invasive bladder cancer. For more information on Anchiano, please visit

Forward-Looking Statements

This press release contains “forward-looking statements” that are subject to risks and uncertainties. Words such as “believes,” “intends,” “expects,” “projects,” “anticipates” and “future” or similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions, many of which are beyond the control of Anchiano, including, without limitation, the risk factors and other matters set forth in its filings with the Securities and Exchange Commission, including its Annual Report on Form 20-F for the year ended December 31, 2018. Anchiano undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

Company Contact:

Frank Haluska, M.D., Ph.D.

President and Chief Executive Officer

Investor Contact:

Ashley R. Robinson

Managing Director

LifeSci Advisors, LLC

617-535-7742

EN
29/05/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Anchiano Therapeutics ADS

 PRESS RELEASE

Anchiano Announces Shareholder Approval of the Merger with Chemomab an...

Anchiano Announces Shareholder Approval of the Merger with Chemomab and Prices $45.5M Private Financing Anchiano shareholders approve all resolutions at shareholder meeting The merged company is expected to receive approximate gross proceeds from the private financing of $45.5 million, which will be used to advance the Chemomab pipeline TEL-AVIV, Israel, March 15, 2021 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (“Anchiano”; Nasdaq: ANCN) and (“Chemomab”), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseas...

 PRESS RELEASE

Anchiano Therapeutics and Chemomab Announce Entry Into Definitive Merg...

Anchiano Therapeutics and Chemomab Announce Entry Into Definitive Merger Agreement Merger brings lead compound CM-101, a first in class anti-CCL24 antibody into advanced clinical development for fibrosis-related diseases with significant unmet medical need Concurrent PIPE financing to be used to fund clinical trials for CM-101 in fibrotic indications, focusing on two rare diseases and backed by leading healthcare-focused investors OrbiMed and Peter Thiel CAMBRIDGE, Mass. and TEL-AVIV, Israel, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (“Anchiano”) (Nasdaq: ANCN), a...

 PRESS RELEASE

Anchiano Appoints Stan Polovets as Chairman of the Board

Anchiano Appoints Stan Polovets as Chairman of the Board CAMBRIDGE, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (the “Company”) today announced that Mr. Stan Polovets has been elected chairman of its board of directors. Mr. Polovets joined the board of Anchiano in April 2020. He previously served as CEO of AAR, a private equity firm with a global energy portfolio valued in excess of $25 billion, and represented TNK in its merger with BP to form one of the world’s largest oil companies and in the eventual sale of the merged company TNK-BP for $55 bill...

 PRESS RELEASE

Anchiano Therapeutics Reports First Quarter 2020 Financial Results

Anchiano Therapeutics Reports First Quarter 2020 Financial Results CAMBRIDGE, Mass., May 11, 2020 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (“Anchiano”), a preclinical biopharmaceutical company dedicated to the discovery and development of new cancer therapies designed to target the products of mutated genes that are drivers of human malignancies, today reported financial results for its first quarter ended March 31, 2020. “We have been very active this quarter and are continuing to transform as a company. We continue to focus on developing our targeted pan-mutant RAS...

 PRESS RELEASE

Anchiano Appoints Steve DiPalma as Chief Financial Officer

Anchiano Appoints Steve DiPalma as Chief Financial Officer CAMBRIDGE, Mass., May 05, 2020 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (the “Company”) today announced it has appointed Mr. Steve DiPalma as its Chief Financial Officer. Mr. DiPalma has served as a Senior Financial Advisor to Anchiano by agreement with Danforth Advisors since 2018; he will succeed Jonathan Burgin, who is leaving the Company as part of the planned closure of the Company’s Israel offices and facilities. Mr. Burgin will remain in the position of Chief Operating Officer until the final closure of...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch